Metsera (MTSR) Stock Price, News & Analysis

Company Overview

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Key Stats

• Today's Range: $32.22 to $34.22
• 50-Day Range: $25.38 to $44.30
• 52-Week Range: $12.30 to $47.40
• Volume: 848,157 shs
• Average Volume: 993,302 shs
• Market Capitalization: $3.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

MTSR Stock Analysis - Frequently Asked Questions

How have MTSR shares performed this year?

Metsera's stock was trading at $29.50 on January 1st, 2025. Since then, MTSR stock has increased by 11.0% and is now trading at $32.74.

How were Metsera's earnings last quarter?

Metsera Inc. (NASDAQ:MTSR) posted its quarterly earnings data on Monday, July, 28th. The company reported ($0.66) earnings per share for the quarter.

When did Metsera IPO?

Metsera (MTSR) raised $275 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $18.00 per share.

When did Metsera's lock-up period expire?

Metsera's lock-up period expired on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its IPO on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. Since the end of Metsera's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Metsera's major shareholders?

Metsera's top institutional shareholders include Alliancebernstein L.P. (1.35%), Geode Capital Management LLC (0.44%), Eventide Asset Management LLC (0.38%) and Jennison Associates LLC (0.30%).

How do I buy shares of Metsera?

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/28/2025
• Today: 8/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTSR
• Previous Symbol: NASDAQ:MTSR
• CIK: 2040807
• Web: N/A
• Phone: (212) 784-6595
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Metsera: $55.00
• High Price Target: $65.00
• Low Price Target: $38.00
• Potential Upside/Downside: +68.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.26
• Quick Ratio: 5.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.46) per share
• Price / Book: -13.31

Miscellaneous

• Outstanding Shares: 105,060,000
• Free Float: N/A
• Market Cap: $3.44 billion
• Optionable: N/A
• Beta: N/A